AstraZeneca
AstraZeneca is a UK-based biopharmaceutical company that discovers, develops, manufactures, and commercialises prescription medicines worldwide. Its portfolio spans oncology, rare disease, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology therapies, with operations in more than 100 countries.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueCancer medicines across multiple tumor types and treatment settings.
Cardiovascular, renal & metabolism, and respiratory & immunology medicines.
Specialty therapies for rare and often severe chronic conditions.
Milestones, royalties, and other income from partnered programs.
Customers
AstraZeneca sells primarily to healthcare systems, hospitals, clinics, and pharmacies that dispense prescription medicines to patients. It also works through government and public-health buyers in certain programs, as well as collaboration partners that help develop, manufacture, or distribute selected products. Demand is driven by physician prescribing, reimbursement access, regulatory approval, and inclusion in treatment protocols.
Buy oncology medicines for use in specialist treatment pathways and infusion settings.
Prescribe respiratory, renal, cardiovascular, and rare disease therapies for chronic care.
Influence access through reimbursement, formulary placement, and procurement decisions.
Purchase vaccines and public-health products through advance purchase or supply agreements.
Share development, manufacturing, and commercialization economics on partnered assets.
Strategy
AstraZeneca’s strategy centers on advancing a deep pipeline, expanding launches in core therapeutic areas, and using business development to add new platforms and assets. The company also emphasizes manufacturing expansion, digital and systems investment, and a progressive dividend policy supported by an investment-grade balance sheet.
Future growth depends on successful clinical readouts, approvals, and commercialization of new medicines.
Global demand and complex biologics require reliable capacity and compliant supply.
Acquisitions and collaborations add new technologies, modalities, and future revenue streams.
The company balances reinvestment with credit quality and a progressive dividend policy.
Geography
AstraZeneca operates globally, with commercial activity in more than 100 countries and a base in Cambridge, UK. Its business is geographically diversified across North America, Europe, and Asia, with emerging markets also important to growth and product mix. Manufacturing, R&D, and supply-chain execution are internationally distributed, which makes the company sensitive to regulatory, currency, and cross-border supply risks.
Risks
AstraZeneca faces typical biopharma risks tied to clinical development, regulatory approval, patent protection, and the ability to launch and scale new medicines. It is also exposed to pricing and access pressure, manufacturing and supply-chain disruption, litigation, cybersecurity, and foreign exchange volatility because its products and operations are global and highly regulated.
- Pipeline and clinical development riskImpact: HighLikelihood: Medium
Drug candidates may fail in trials, miss endpoints, or be delayed by regulators.
Exposure - Intellectual property and patent challengesImpact: HighLikelihood: Medium
Loss of exclusivity or adverse IP rulings can accelerate generic or biosimilar competition.
Exposure: Key marketed medicines and future launches
- Pricing, affordability, and access pressureImpact: HighLikelihood: Medium
Payers and governments can restrict reimbursement or negotiate lower prices.
Exposure: Global prescription medicine portfolio
- Manufacturing and supply-chain executionImpact: MediumLikelihood: Medium
Biologics and global distribution require compliant, uninterrupted supply.
Exposure: Global production and third-party suppliers
- Legal and regulatory complianceImpact: MediumLikelihood: Medium
Product liability, antitrust, and anti-corruption issues can lead to fines or restrictions.
Exposure: Commercial practices and marketed medicines
Accounting
Judgemental itemsPartnered programs can generate irregular revenue tied to events rather than steady sales.
Impact: Affects quarterly comparability and revenue mix
AstraZeneca records product sales in some markets but shares gross profit with partners.
Impact: Influences gross margin and cost of sales
Acquired pipelines and technologies are valued using assumptions about peak sales and erosion.
Impact: Affects goodwill, intangible assets, and future amortization
Litigation and investigations can require judgment on probability and loss estimates.
Impact: Can materially affect expenses and balance sheet reserves
The company hedges transactional exposures and dividend payments in multiple currencies.
Impact: Affects earnings timing and OCI
Similar listed companies
Publicly listed companies with a comparable business focus.
Healthier Choices Management Corp.
HCMC · Tobacco Products
Hong Yuan Holding Group
HGYN · Plastic Materials, Synth Resins & Nonvulcan Elastomers
HONG YUAN HOLDING GROUP is a U.S.-listed company in the plastics and synthetic resins value chain.
Valuence Merger Corp. I
VMCUF · Blank Checks
Valuence Merger Corp.
American Exceptionalism Acquisition Corp. A
AEXA · Blank Checks
American Exceptionalism Acquisition Corp.
Artificial Intelligence Technology Solutions Inc.
AITX · Services-Prepackaged Software
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026